Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Return on Equity (2021 - 2025)

Candel Therapeutics' Return on Equity history spans 3 years, with the latest figure at 0.02% for Q4 2023.

  • On a quarterly basis, Return on Equity fell 1.0% to 0.02% in Q4 2023 year-over-year; TTM through Dec 2023 was 0.02%, a 1.0% decrease, with the full-year FY2023 number at 0.01%, down 1.0% from a year prior.
  • Return on Equity hit 0.02% in Q4 2023 for Candel Therapeutics, down from 0.01% in the prior quarter.
  • Over the last five years, Return on Equity for CADL hit a ceiling of 0.01% in Q1 2021 and a floor of 0.02% in Q3 2021.
  • Historically, Return on Equity has averaged 0.01% across 3 years, with a median of 0.01% in 2022.
  • The widest YoY moves for Return on Equity: up 2bps in 2022, down -1bps in 2022.
  • Tracing CADL's Return on Equity over 3 years: stood at 0.0% in 2021, then crashed by -74bps to 0.01% in 2022, then plummeted by -208bps to 0.02% in 2023.
  • Business Quant data shows Return on Equity for CADL at 0.02% in Q4 2023, 0.01% in Q3 2023, and 0.01% in Q2 2023.